Malcova is eliminating pain (no breast compression), reducing harm (40% lower radiation), and saving lives (true early detection with clear imaging) through a paradigm shift in breast cancer diagnosis -detecting the earliest signs of malignancy even in dense tissue (c50% of women). Their solution is protected by a strong IP and tech moat (6 patents). They collaborate with Stanford, UC Davis and Johns Hopkins and are moving into a clinical study with Yale Q1 2026. The founders are scientist-entrepreneurs, they have raised $6M+ of non-dilutive funding so far and are currently raising a $4m seed VC round (matched $1 for $1 with further non-dilutive NIH grant funding) as they move into their patient studies.
Book a Meeting